GoodRx Holdings, Inc. (NASDAQ:GDRX) Given Average Rating of “Moderate Buy” by Brokerages

GoodRx Holdings, Inc. (NASDAQ:GDRX) has been given a consensus rating of “Moderate Buy” by the ten analysts that are covering the stock, MarketBeat.com reports. Three research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $8.18.

A number of research firms have recently commented on GDRX. Citigroup cut their price target on shares of GoodRx from $7.00 to $6.25 and set a “buy” rating on the stock in a report on Friday, January 10th. KeyCorp cut their price target on GoodRx from $7.00 to $6.00 and set an “overweight” rating on the stock in a report on Wednesday, January 8th. Morgan Stanley decreased their price target on shares of GoodRx from $7.00 to $6.00 and set an “equal weight” rating for the company in a research report on Tuesday, December 17th. Finally, Wells Fargo & Company cut their price objective on shares of GoodRx from $9.00 to $8.00 and set an “overweight” rating on the stock in a research report on Friday, February 28th.

GoodRx Trading Down 2.7 %

Shares of NASDAQ GDRX opened at $4.01 on Tuesday. The business’s 50 day moving average price is $4.71 and its 200-day moving average price is $5.14. GoodRx has a fifty-two week low of $3.82 and a fifty-two week high of $9.26. The company has a debt-to-equity ratio of 0.70, a quick ratio of 5.48 and a current ratio of 5.48. The company has a market cap of $1.54 billion, a price-to-earnings ratio of -133.67, a PEG ratio of 2.46 and a beta of 1.25.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in GDRX. Vanguard Group Inc. increased its position in shares of GoodRx by 5.8% in the 4th quarter. Vanguard Group Inc. now owns 8,373,039 shares of the company’s stock valued at $38,935,000 after acquiring an additional 460,753 shares during the period. Dimensional Fund Advisors LP grew its stake in GoodRx by 22.8% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,992,311 shares of the company’s stock valued at $9,264,000 after purchasing an additional 369,553 shares during the last quarter. Point72 Asset Management L.P. acquired a new position in shares of GoodRx in the third quarter valued at about $11,295,000. Clearbridge Investments LLC purchased a new position in shares of GoodRx in the fourth quarter worth about $5,863,000. Finally, Connor Clark & Lunn Investment Management Ltd. lifted its holdings in shares of GoodRx by 38.7% during the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 1,228,836 shares of the company’s stock worth $5,714,000 after purchasing an additional 342,781 shares during the period. Hedge funds and other institutional investors own 63.77% of the company’s stock.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.